DE2965284D1 - Pharmaceutical compositions for topical administration containing prostaglandins - Google Patents

Pharmaceutical compositions for topical administration containing prostaglandins

Info

Publication number
DE2965284D1
DE2965284D1 DE7979301602T DE2965284T DE2965284D1 DE 2965284 D1 DE2965284 D1 DE 2965284D1 DE 7979301602 T DE7979301602 T DE 7979301602T DE 2965284 T DE2965284 T DE 2965284T DE 2965284 D1 DE2965284 D1 DE 2965284D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
topical administration
administration containing
containing prostaglandins
prostaglandins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE7979301602T
Other languages
English (en)
Inventor
Jay Edward Birnbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of DE2965284D1 publication Critical patent/DE2965284D1/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE7979301602T 1978-08-16 1979-08-07 Pharmaceutical compositions for topical administration containing prostaglandins Expired DE2965284D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/934,199 US4254145A (en) 1978-08-16 1978-08-16 Topical application of prostaglandin hypotensive agents

Publications (1)

Publication Number Publication Date
DE2965284D1 true DE2965284D1 (en) 1983-09-01

Family

ID=25465143

Family Applications (1)

Application Number Title Priority Date Filing Date
DE7979301602T Expired DE2965284D1 (en) 1978-08-16 1979-08-07 Pharmaceutical compositions for topical administration containing prostaglandins

Country Status (7)

Country Link
US (1) US4254145A (de)
EP (1) EP0008227B1 (de)
JP (1) JPS5536494A (de)
AU (1) AU530454B2 (de)
CA (1) CA1134270A (de)
DE (1) DE2965284D1 (de)
ZA (1) ZA792935B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4564637A (en) * 1981-08-19 1986-01-14 Schachar Ronald A Method for maintaining corneal shape after radial keratotomy
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
JPS5948409A (ja) * 1982-09-10 1984-03-19 Teikoku Seiyaku Kk 矯正的歯牙移動促進剤
US4450175A (en) * 1982-09-23 1984-05-22 Warshaw Thelma G Method and compositions for treating acne
JPS59128327A (ja) * 1983-01-10 1984-07-24 Teijin Ltd ７−チアプロスタグランジンｅ↓１類を有効成分とする経皮投与用薬剤
US5723502A (en) * 1985-07-18 1998-03-03 Proctor; Peter H. Topical spin trap composition and method
US5716947A (en) * 1985-07-18 1998-02-10 Proctor; Peter H. Topical doxyl composition and method
US5472687A (en) * 1985-07-18 1995-12-05 Proctor; Peter H. Topical pyridine N-oxides
US5714482A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical spin labels and method
US5352442A (en) * 1985-07-18 1994-10-04 Proctor Peter H Topical tempo
US5728714A (en) * 1985-07-18 1998-03-17 Proctor; Peter H. Method for treating hair loss using tempo
US6150405A (en) * 1985-07-18 2000-11-21 Proctor; Peter H. Hair loss treatment with ascorbates
US5470876A (en) * 1985-07-18 1995-11-28 Proctor; Peter H. Topical sod for treating hair loss
US5714510A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical proxyl composition and method
US4707495A (en) * 1985-10-28 1987-11-17 Ortho Pharmaceutical Peptic ulcer treatment method
AU602509B2 (en) * 1986-03-13 1990-10-18 Trustees Of Columbia University In The City Of New York, The Use of A,B and C prostaglandins and derivatives therof to treat ocular hypertension and glaucoma
US5164416A (en) * 1989-02-03 1992-11-17 Lintec Corporation Transdermal therapeutic formulation containing a limonene
US5262437A (en) * 1990-12-10 1993-11-16 Allergan, Inc. Homo-prostaglandin derivatives as ocular hypotensives
CA2096944A1 (en) * 1990-12-10 1992-06-11 Ming Fai Chan Homo-prostaglandin derivatives as ocular hypotensives
US5578643A (en) * 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
WO1994017806A1 (en) * 1993-02-03 1994-08-18 Teijin Limited Dermatologic preparation composition containing prostacyclin as active ingredient
WO1994017805A1 (en) * 1993-02-03 1994-08-18 Teijin Limited Dermatologic preparation composition containing isocarbacyclin as active ingredient
US5324746A (en) * 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
US6007836A (en) * 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
SE9403158D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab New use of prostaglandins
US5994399A (en) * 1997-03-27 1999-11-30 Mckee; Rex N. Method of regenerating collagen-containing tissues with misoprostol
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
AU742787B2 (en) 1997-07-09 2002-01-10 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
US6593369B2 (en) 1997-10-20 2003-07-15 Vivus, Inc. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US20050070516A1 (en) * 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
CA2306837C (en) 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
CA2340206A1 (en) * 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti-pressor agents for vascular remodeling in genital dysfunction
US20070191320A1 (en) * 1998-12-10 2007-08-16 Nexmed Holdings, Inc. Methods of treatment for female sexual arousal disorder
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
ATE419844T1 (de) * 2000-02-10 2009-01-15 Kao Corp Verwendung von sesquiterpenalkohol zur regulierung des autonomen nervensystems
US20040087484A1 (en) * 2000-12-01 2004-05-06 Sahota Pritam Singh Combination of organic compounds
AU2003209150A1 (en) * 2002-01-04 2003-07-24 Combinatorx, Incorporated Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
US20060100181A1 (en) * 2002-05-03 2006-05-11 Jost-Price Edward R Combinations for the treatment of inflammatory skin disorders
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7241746B2 (en) * 2003-08-06 2007-07-10 Regena Therapeutics, Lc Method and composition for treating periodontal disease
US20090124697A1 (en) 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
ATE473736T1 (de) * 2003-12-16 2010-07-15 United Therapeutics Corp Verwendung von treprostinil zur behandlung von ischämischen läsionen
SE0402029D0 (sv) * 2004-08-17 2004-08-17 Synphora Ab Prostaglandin a derivatieves for the treatment of psoriasis
DK1853271T3 (da) * 2005-03-04 2011-01-24 Sucampo Ag Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
US20070254861A1 (en) * 2006-04-28 2007-11-01 Astellas Pharma Inc. Methods for the prevention and/or treatment of peripheral arterial disease
US20120251613A1 (en) * 2011-03-29 2012-10-04 Agila Specialities Pvt. Ltd. Method for treating vitiligo with a prostaglandin analogue
BR112014008190A2 (pt) * 2011-10-05 2017-04-18 Allergan Inc composições para realce da saúde da unha
FR2984167B1 (fr) * 2011-12-16 2014-01-17 Galderma Res & Dev Association d'un agoniste des recepteurs des prostaglandines et d'un agoniste du recepteur mc1r pour le traitement et/ou la prevention de desordres de la pigmentation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US4094899A (en) * 1972-06-02 1978-06-13 Pfizer Inc. Oxaprostaglandins
FR2235678A1 (en) * 1973-07-02 1975-01-31 Merck & Co Inc Topical antipsoriasis agents - contg. prostaglandin E1 or E2
DE2346706A1 (de) * 1973-09-17 1975-04-03 Hoechst Ag Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US4009282A (en) * 1973-12-17 1977-02-22 The Regents Of The University Of Michigan Treatment of proliferating skin diseases with prostaglandins
US3919302A (en) * 1974-02-28 1975-11-11 American Home Prod 11,15 Dimethyl-11 deoxy PGF{HD 2 {B
US4080506A (en) * 1974-08-14 1978-03-21 The Upjohn Company Phenacyl-type esters of PGA1 and PGA2
US4028396A (en) * 1975-07-02 1977-06-07 American Cyanamid Company 16,16-Spirocycloalkyl prostaglandin derivatives
US4061670A (en) * 1976-07-19 1977-12-06 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl and cyclopropyl substituted prostanoic acids and congeners
US4103026A (en) * 1976-08-23 1978-07-25 Carlson Lars A Treatment of peripheral vascular disease by non-intraarterial administration of prostaglandin E1
US4154954A (en) * 1977-03-30 1979-05-15 American Cyanamid Company 11-(2-Hydroxyethylthio) prostenoic acid E series derivatives
US4154959A (en) * 1977-03-30 1979-05-15 American Cyanamid Company 11-(2-Hydroxyethylthio)prostenoic acid E series derivatives
US4085272A (en) * 1977-03-30 1978-04-18 American Cyanamid Company 11-(2-Hydroxyethylthio)prostenoic acid E2 series derivatives
CA1148149A (en) * 1977-12-08 1983-06-14 Allan Wissner Prostaglandin activity

Also Published As

Publication number Publication date
AU4917179A (en) 1980-02-21
JPS5536494A (en) 1980-03-14
AU530454B2 (en) 1983-07-14
CA1134270A (en) 1982-10-26
ZA792935B (en) 1980-06-25
EP0008227A1 (de) 1980-02-20
US4254145A (en) 1981-03-03
EP0008227B1 (de) 1983-04-27

Similar Documents

Publication Publication Date Title
DE2965284D1 (en) Pharmaceutical compositions for topical administration containing prostaglandins
NZ184060A (en) Sprayable pharmaceutical composition for topical administration
NZ189574A (en) Dehydrocyclicimino acid derivatives pharmaceutical compositions
GB2039738B (en) Inflammation - preventing pharmaceutical composition
GB2148711B (en) Topical pharmaceutical compositions
NZ191044A (en) Imidazole derivatives pharmaceutical compositions
JPS5579321A (en) Medical composition for local administration
NZ189939A (en) N-oxacyclic-alkylpiperidyl-diaza compounds pharmaceutical compositions
GB2041219B (en) Topical pharmaceutical compositions containing thiazolidine-substituted corticosteroids
NZ189684A (en) Substituted 2-phenylimino-imidazolidines pharmaceutical compositions
IL56435A0 (en) Pharmaceutical compositions containing prostaglandins
IL56577A (en) Pharmaceutical compositions comprising certain 1-substituted-2-pyrrolidinones
GB1548837A (en) Compositions containing medicament for topical application
ZA79395B (en) Pharmaceutical formulations
NZ190810A (en) 1-aminoalkyl-3-phenoxy-propan-2-ol derivatives pharmaceutical compositions
GB2026863B (en) Pharmaceutical compositions containing aziridine derivatives
GB2034587B (en) Pharmaceutical compositions
GB2039218B (en) Pharmaceutical compositions
GB2031727B (en) Pharmaceutical compositions
JPS54154516A (en) Pharmaceutical composition
IL57254A0 (en) Pharmaceutical compositions containing azepine derivatives
DE2964817D1 (en) Pharmaceutical compositions containing two beta-lactam derivatives
ZA794484B (en) Pharmaceutical compositions
AU523405B2 (en) Pharmaceutical compositions
NZ190958A (en) 2-phenylamino-2-imidazoline derivatives pharmaceutical compositions

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee